Metronidazole Ointment in Non-healing Pilonidal Sinus Wounds
NCT ID: NCT04273997
Last Updated: 2021-09-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-10-01
Study Completion Date
2022-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Title of Study:
Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution on non-healing pilonidal sinus wounds Medical Condition Under Investigation Non-healing pilonidal sinus wounds
Study centres: 2 Centres in Turkey
Clinical Phase: Phase 2
Protocol Number: MET-PS-02
Study Design: Randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of metronidazole ointment applied to the wound, following debridement in non-healing pilonidal sinus wounds.
Planned Sample Size: 80 subjects
Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution on non-healing pilonidal sinus wounds Medical Condition Under Investigation Non-healing pilonidal sinus wounds
Study centres: 2 Centres in Turkey
Clinical Phase: Phase 2
Protocol Number: MET-PS-02
Study Design: Randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of metronidazole ointment applied to the wound, following debridement in non-healing pilonidal sinus wounds.
Planned Sample Size: 80 subjects
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds
NCT01434914
Ulcus Cruris
TERMINATED
PHASE4
Study on the Mechanism of Zuoqing San Promoting Postoperative Wound Healing of Anal Fistula by Inhibiting ROS-dependent NETosis
NCT07128953
Anal Fistula
ENROLLING_BY_INVITATION
EARLY_PHASE1
Phase Ⅱ Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Venous Leg
NCT05319106
Venous Leg Ulcer
RECRUITING
NA
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
NCT02394821
Neoplasm
Wounds and Injuries
COMPLETED
PHASE3
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
NCT07089602
Diabetic Foot
DFU
Diabetic Foot Ulcer
+6 more
RECRUITING
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Route of Administration: Cutaneous
Investigational product and dosage:
Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound.
Comparator and dosage:
Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound.
Maximum Duration of Treatment:
The subject's participation in the study will last 10 weeks (including 2 week screening, 6 weeks clinical phase and 2 week follow-up phase).
Procedures:
Recruitment:
Subjects will be recruited through surgical out-patient clinics who will be contacted directly or through advertisements. Potential Subjects will have the opportunity to read or hear the study advertisement and contact the researcher through the contact details provided. Potential participants will have the opportunity to ask any questions to the researchers.
A member of the research team will then send a copy of the information sheet (either by email or post) or hand to the participant, who will have the opportunity to ask any questions to the researchers, either by email or phone.
Subjects expressing an interest in participating will be interviewed at their scheduled clinic appointment to explain the study in detail, and discuss the risks, benefits, goals and limitations of the study by the treating nurse.
Screening:
Potentially eligible Subjects will provide written informed consent prior to any study specific procedures being conducted.
Following the provision of written, informed consent, the Subject's demography, medical history, especially that relating to pilonidal sinus including details on surgical interventions, will be documented. Female Subjects of child-bearing potential will undergo a urine pregnancy test. Following a physical examination, height, weight and checks on vital signs, the Subjects will have blood samples drawn for routine haematology and biochemistry analyses. Subjects will be asked to provide details of any concomitant medications. The wound will be sized and graded using the Pressure Ulcer Scale for Healing (PUSH) tool 3.0. Subjects will have their wound assessed, then debrided and any surrounding hair removed by shaving, cleaned and dressed in accordance with normal management procedures.
Subjects with a confirmed diagnosis of non-healing pilonidal sinus wound, compliance with the inclusion and exclusion criteria and providing written informed consent will be registered on the electronic case report form (eCRF) to obtain a screening number.
The Investigator will demonstrate to the subject how to clean and dress the wound.
The subject will be educated on the use of the diary and asked to record at the end of each day the number of times they cleaned and dressed the wound and any changes in their condition or concomitant medication. Subjects will be asked to complete the diary over the subsequent 2 weeks.
Subjects not wishing to participate, or who are ineligible, will be followed up in accordance with the clinic's standard management procedures.
Baseline:
The subject will attend the clinic and the diary will be reviewed to ensure completion of the diary, the number of times the wound was cleaned and dressed, any changes in their condition or concomitant medications. Haematology and biochemistry test (from Screening) results will be confirmed as being acceptable.
Subjects will have the status of their pilonidal disease assessed and the wound will be sized and graded using the Pressure Ulcer Scale for Healing (PUSH) tool 3.0, to confirm that it remains unhealed with no improvement.
Subjects demonstrating improvement in the wound and healing in the screening period, will be followed up in accordance with the clinic's standard management procedures.
Female Subjects of child-bearing potential will undergo a pregnancy test. Subjects compliant with the inclusion and exclusion criteria will be randomised on a 1:1 basis to one of the two treatment groups: metronidazole 10%w/w ointment or matching placebo ointment. Randomisation will be stratified by wound size less than 3cm.
Following a physical examination, weight and checks on vital signs, blood samples will be drawn for routine haematology and biochemistry analyses. The wound will be swabbed for microbial analysis, then debrided and any surrounding hair removed by shaving.
The subject will be provided with two pre-weighed tubes of IMP together with a supply of sterile dressings. The Investigator will demonstrate to the subject how to apply 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape.
The subject will be retrained on completion of the diary and asked to record each day confirmation of wound cleansing, IMP dose application and wound dressing as well as any changes in their condition or concomitant medication.
Week 1:
One week after randomisation, the subject will be contacted by telephone to check on their progress, compliance with study medication, concomitant medications and the occurrence of any adverse events.
Weeks 2, 4 and 6 :
Two, four and six weeks after randomisation, the subject will attend the clinic for review of the healing status of their pilonidal disease including sizing of the wound and assignment of a PUSH score, together with checks on vital signs and a physical examination. In addition, the subject will complete the PGI I in relation to their pilonidal disease, relative to the baseline condition.
Haematology and biochemistry test (from Baseline) results will be confirmed as being acceptable (Week 2 Visit only).
At each visit the IMP tubes will be weighed to determine the amount used as a check on compliance with study treatment. The subject diary will be reviewed and any changes in symptoms and concomitant medications registered in the eCRF.
The Investigator will clean the wound and remove any surrounding hair by shaving. During each visit apply the dose of IMP and dress the wound for that day (Week 2 and Week 4 Visits only).
At the Week 6 visit, subjects will also provide blood samples for routine haematology and biochemistry analyses. Female subjects of child-bearing potential will undergo a pregnancy test. Subjects considered a clinical failure will have the pilonidal sinus wound swabbed for microbiological analysis.
In the event that the wound is judged to be completely healed at any visit, the subject will be instructed to stop applying the study medication. The Week 6 procedures will be performed and the subject will be asked to attend the clinic after a further 2 weeks, when the Week 8 procedures will be undertaken.
In the event that a subject wishes to withdraw prior to the end of the study, they will be asked to undertake the Week 6 procedures.
For subjects who have failed to heal, appropriate post-study treatment will be instituted.
Week 8 (follow-up):
Eight weeks after randomisation (or two weeks after a visit at which complete healing is confirmed), the subject will attend the clinic for review of the healing status of the pilonidal disease including wound size and PUSH score, together with checks on vital signs, changes in symptoms and concomitant medications. The subject will complete the PGI I in relation to their pilonidal disease, relative to the baseline condition. Haematology and biochemistry test (from Week 6 Visit) results will be confirmed as being acceptable.
Blood and urine sampling:
A blood sample will be drawn at the Screening, Baseline and Week 6 Visits for routine haematology and biochemistry tests.
Urine pregnancy tests will be conducted at Screening, Baseline and Week 6 Visits.
Safety Parameters:
Study subjects will be asked to record any changes in symptoms in the diary provided on a daily basis. This will be reviewed at each study visit and any adverse events will be documented in the eCRF. Changes in vital signs and outcome of routine blood analyses will be evaluated.
Adverse events (AEs) will be classified using a coding thesaurus (MedDRA).
Primary Endpoint:
Complete wound healing by Week 6.
Secondary Endpoints:
* Rate of wound healing \[(baseline mm3 - Current mm3) / baseline mm3 x 100%
* Proportion of subjects with complete healing by Week 2 and 4
* Proportion of subjects with complete healing maintained over two consecutive visits
* Time to response, defined as complete healing
* Change from baseline in PUSH score at Weeks 2, 4 and 6
* Patient's Global Impression of Improvement (PGI-I) at Weeks 2, 4 and 6
Safety Endpoints:
The safety analysis will be conducted in all randomised subjects receiving at least one dose.
* Number and proportion of subjects with adverse events.
* Assessment of clinical laboratory parameters.
* Assessment of vital signs.
Statistical Analyses:
Proportion of subjects with complete healing and with partial healing will be presented using point estimates with 95% confidence intervals.
Differences in the rates of healing will be determined by difference in the mean. SE of the mean and 95% confidence interval will be reported.
Time to response will be presented in Kaplan-Meier curves. PUSH score will be presented by using point estimates with 95% confidence intervals. Comparisons between each treatment and placebo will be based on an Analysis of covariance (ANCOVA) model.
PGI-I will be presented by category using point estimates with 95% confidence intervals. Comparisons between each treatment and placebo will be based on a proportional odds model.
AEs will be classified into standard terminology using a coding thesaurus (MedDRA). Treatment-related AEs will be summarised separately from all AEs. In addition, the maximum intensity of AEs will be summarised. For AEs these will be summarized using descriptive statistics. Results of laboratory tests and measures of vital signs will be presented as summary statistics and as shift tables.
Missing data will be handled using a worst observation carried forward (WOCF) imputation. Sensitivity analyses will be included in the SAP.
Investigational product and dosage:
Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound.
Comparator and dosage:
Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound.
Maximum Duration of Treatment:
The subject's participation in the study will last 10 weeks (including 2 week screening, 6 weeks clinical phase and 2 week follow-up phase).
Procedures:
Recruitment:
Subjects will be recruited through surgical out-patient clinics who will be contacted directly or through advertisements. Potential Subjects will have the opportunity to read or hear the study advertisement and contact the researcher through the contact details provided. Potential participants will have the opportunity to ask any questions to the researchers.
A member of the research team will then send a copy of the information sheet (either by email or post) or hand to the participant, who will have the opportunity to ask any questions to the researchers, either by email or phone.
Subjects expressing an interest in participating will be interviewed at their scheduled clinic appointment to explain the study in detail, and discuss the risks, benefits, goals and limitations of the study by the treating nurse.
Screening:
Potentially eligible Subjects will provide written informed consent prior to any study specific procedures being conducted.
Following the provision of written, informed consent, the Subject's demography, medical history, especially that relating to pilonidal sinus including details on surgical interventions, will be documented. Female Subjects of child-bearing potential will undergo a urine pregnancy test. Following a physical examination, height, weight and checks on vital signs, the Subjects will have blood samples drawn for routine haematology and biochemistry analyses. Subjects will be asked to provide details of any concomitant medications. The wound will be sized and graded using the Pressure Ulcer Scale for Healing (PUSH) tool 3.0. Subjects will have their wound assessed, then debrided and any surrounding hair removed by shaving, cleaned and dressed in accordance with normal management procedures.
Subjects with a confirmed diagnosis of non-healing pilonidal sinus wound, compliance with the inclusion and exclusion criteria and providing written informed consent will be registered on the electronic case report form (eCRF) to obtain a screening number.
The Investigator will demonstrate to the subject how to clean and dress the wound.
The subject will be educated on the use of the diary and asked to record at the end of each day the number of times they cleaned and dressed the wound and any changes in their condition or concomitant medication. Subjects will be asked to complete the diary over the subsequent 2 weeks.
Subjects not wishing to participate, or who are ineligible, will be followed up in accordance with the clinic's standard management procedures.
Baseline:
The subject will attend the clinic and the diary will be reviewed to ensure completion of the diary, the number of times the wound was cleaned and dressed, any changes in their condition or concomitant medications. Haematology and biochemistry test (from Screening) results will be confirmed as being acceptable.
Subjects will have the status of their pilonidal disease assessed and the wound will be sized and graded using the Pressure Ulcer Scale for Healing (PUSH) tool 3.0, to confirm that it remains unhealed with no improvement.
Subjects demonstrating improvement in the wound and healing in the screening period, will be followed up in accordance with the clinic's standard management procedures.
Female Subjects of child-bearing potential will undergo a pregnancy test. Subjects compliant with the inclusion and exclusion criteria will be randomised on a 1:1 basis to one of the two treatment groups: metronidazole 10%w/w ointment or matching placebo ointment. Randomisation will be stratified by wound size less than 3cm.
Following a physical examination, weight and checks on vital signs, blood samples will be drawn for routine haematology and biochemistry analyses. The wound will be swabbed for microbial analysis, then debrided and any surrounding hair removed by shaving.
The subject will be provided with two pre-weighed tubes of IMP together with a supply of sterile dressings. The Investigator will demonstrate to the subject how to apply 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape.
The subject will be retrained on completion of the diary and asked to record each day confirmation of wound cleansing, IMP dose application and wound dressing as well as any changes in their condition or concomitant medication.
Week 1:
One week after randomisation, the subject will be contacted by telephone to check on their progress, compliance with study medication, concomitant medications and the occurrence of any adverse events.
Weeks 2, 4 and 6 :
Two, four and six weeks after randomisation, the subject will attend the clinic for review of the healing status of their pilonidal disease including sizing of the wound and assignment of a PUSH score, together with checks on vital signs and a physical examination. In addition, the subject will complete the PGI I in relation to their pilonidal disease, relative to the baseline condition.
Haematology and biochemistry test (from Baseline) results will be confirmed as being acceptable (Week 2 Visit only).
At each visit the IMP tubes will be weighed to determine the amount used as a check on compliance with study treatment. The subject diary will be reviewed and any changes in symptoms and concomitant medications registered in the eCRF.
The Investigator will clean the wound and remove any surrounding hair by shaving. During each visit apply the dose of IMP and dress the wound for that day (Week 2 and Week 4 Visits only).
At the Week 6 visit, subjects will also provide blood samples for routine haematology and biochemistry analyses. Female subjects of child-bearing potential will undergo a pregnancy test. Subjects considered a clinical failure will have the pilonidal sinus wound swabbed for microbiological analysis.
In the event that the wound is judged to be completely healed at any visit, the subject will be instructed to stop applying the study medication. The Week 6 procedures will be performed and the subject will be asked to attend the clinic after a further 2 weeks, when the Week 8 procedures will be undertaken.
In the event that a subject wishes to withdraw prior to the end of the study, they will be asked to undertake the Week 6 procedures.
For subjects who have failed to heal, appropriate post-study treatment will be instituted.
Week 8 (follow-up):
Eight weeks after randomisation (or two weeks after a visit at which complete healing is confirmed), the subject will attend the clinic for review of the healing status of the pilonidal disease including wound size and PUSH score, together with checks on vital signs, changes in symptoms and concomitant medications. The subject will complete the PGI I in relation to their pilonidal disease, relative to the baseline condition. Haematology and biochemistry test (from Week 6 Visit) results will be confirmed as being acceptable.
Blood and urine sampling:
A blood sample will be drawn at the Screening, Baseline and Week 6 Visits for routine haematology and biochemistry tests.
Urine pregnancy tests will be conducted at Screening, Baseline and Week 6 Visits.
Safety Parameters:
Study subjects will be asked to record any changes in symptoms in the diary provided on a daily basis. This will be reviewed at each study visit and any adverse events will be documented in the eCRF. Changes in vital signs and outcome of routine blood analyses will be evaluated.
Adverse events (AEs) will be classified using a coding thesaurus (MedDRA).
Primary Endpoint:
Complete wound healing by Week 6.
Secondary Endpoints:
* Rate of wound healing \[(baseline mm3 - Current mm3) / baseline mm3 x 100%
* Proportion of subjects with complete healing by Week 2 and 4
* Proportion of subjects with complete healing maintained over two consecutive visits
* Time to response, defined as complete healing
* Change from baseline in PUSH score at Weeks 2, 4 and 6
* Patient's Global Impression of Improvement (PGI-I) at Weeks 2, 4 and 6
Safety Endpoints:
The safety analysis will be conducted in all randomised subjects receiving at least one dose.
* Number and proportion of subjects with adverse events.
* Assessment of clinical laboratory parameters.
* Assessment of vital signs.
Statistical Analyses:
Proportion of subjects with complete healing and with partial healing will be presented using point estimates with 95% confidence intervals.
Differences in the rates of healing will be determined by difference in the mean. SE of the mean and 95% confidence interval will be reported.
Time to response will be presented in Kaplan-Meier curves. PUSH score will be presented by using point estimates with 95% confidence intervals. Comparisons between each treatment and placebo will be based on an Analysis of covariance (ANCOVA) model.
PGI-I will be presented by category using point estimates with 95% confidence intervals. Comparisons between each treatment and placebo will be based on a proportional odds model.
AEs will be classified into standard terminology using a coding thesaurus (MedDRA). Treatment-related AEs will be summarised separately from all AEs. In addition, the maximum intensity of AEs will be summarised. For AEs these will be summarized using descriptive statistics. Results of laboratory tests and measures of vital signs will be presented as summary statistics and as shift tables.
Missing data will be handled using a worst observation carried forward (WOCF) imputation. Sensitivity analyses will be included in the SAP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pilonidal Sinus
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution of non-healing pilonidal sinus wounds
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
double blinded
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metronidazole Ointment
Treatment Group A: Metronidazole 10% w/w ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose contains approximately 70 mg metronidazole in a formulation of white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound
Group Type
ACTIVE_COMPARATOR
Metronidazole 10% ointment
Intervention Type
DRUG
Metronidazole 10% ointment
Placebo Ointment
Treatment Group B: Placebo ointment. A 2.5 cm strip of ointment (approximately 700 mg) will be administered topically to the wound together with suitable dressing, once daily.
One dose of placebo ointment contains titanium dioxide and white soft paraffin. The Investigator will demonstrate to the subject how to apply a 2.5 cm of IMP and dress the wound by applying the first dose and covering with a dry, gauze dressing which is to be retained with tape. Larger wounds may require additional amount of IMP to ensure sufficient cover of the wound.
Group Type
PLACEBO_COMPARATOR
Placebo ointment
Intervention Type
DRUG
Placebo ointment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metronidazole 10% ointment
Metronidazole 10% ointment
Intervention Type
DRUG
Placebo ointment
Placebo ointment
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Ortem
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Must give written informed consent.
2. Male or female aged ≥18 years.
3. Previous surgery for pilonidal disease and failure of healing for ≥ 6 weeks post-surgical excision of the pilonidal cyst/sinus;
4. Willingness to stop all other concomitant topical preparations at the site of pilonidal sinus wounds.
2. Male or female aged ≥18 years.
3. Previous surgery for pilonidal disease and failure of healing for ≥ 6 weeks post-surgical excision of the pilonidal cyst/sinus;
4. Willingness to stop all other concomitant topical preparations at the site of pilonidal sinus wounds.
Exclusion Criteria
The subject will be excluded from the study if any of the following applies:
1. Presence of non-drained abscess (abscess must have been drained ≥ 6 weeks prior to entry).
2. Subjects who are due to undergo surgery related to pilonidal sinus.
3. Previous use (in the last 2 weeks) or current treatment with any antibiotic. To be determined by medical history prior to screening.
4. Previous treatment with topical metronidazole for pilonidal sinus.
5. Known allergic reaction to metronidazole.
6. Known allergic reaction to excipients of IMP and placebo.
7. Subject is taking any prohibited medication (warfarin-type anticoagulants, fluorouracil, glucocorticoids, other topical preparations to the area of the wound, lithium, cyclosporin and disulfiram).
8. Experimental agents must have been discontinued at least 8 weeks prior to screening or for a period equivalent to 5 half-lives of the agent (whichever is longer).
9. History of epilepsy or seizures.
10. Subject has hepatic insufficiency as defined by laboratory values outside the normal ranges.
11. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined oestrogen and progestogen containing hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\], intrauterine hormone-releasing system \[IUS\], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide \[double barrier methods\]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels that have been confirmed to be in the "postmenopausal range". Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.
12. Women who are pregnant or breastfeeding at baseline.
13. Subjects with concurrent disease considered by the Investigator to be clinically significant in the context of the study.
14. Subjects who have clinically significant abnormalities on their screening blood tests. "Clinically significant" will be determined by the surgeon at the study site.
15. Subjects who will be unavailable for the duration of the trial, deemed unable to comply with the requirements of the study protocol, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.
16. Subjects who show a 20% reduction in wound size between screening and baseline.
1. Presence of non-drained abscess (abscess must have been drained ≥ 6 weeks prior to entry).
2. Subjects who are due to undergo surgery related to pilonidal sinus.
3. Previous use (in the last 2 weeks) or current treatment with any antibiotic. To be determined by medical history prior to screening.
4. Previous treatment with topical metronidazole for pilonidal sinus.
5. Known allergic reaction to metronidazole.
6. Known allergic reaction to excipients of IMP and placebo.
7. Subject is taking any prohibited medication (warfarin-type anticoagulants, fluorouracil, glucocorticoids, other topical preparations to the area of the wound, lithium, cyclosporin and disulfiram).
8. Experimental agents must have been discontinued at least 8 weeks prior to screening or for a period equivalent to 5 half-lives of the agent (whichever is longer).
9. History of epilepsy or seizures.
10. Subject has hepatic insufficiency as defined by laboratory values outside the normal ranges.
11. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined oestrogen and progestogen containing hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\], intrauterine hormone-releasing system \[IUS\], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide \[double barrier methods\]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels that have been confirmed to be in the "postmenopausal range". Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.
12. Women who are pregnant or breastfeeding at baseline.
13. Subjects with concurrent disease considered by the Investigator to be clinically significant in the context of the study.
14. Subjects who have clinically significant abnormalities on their screening blood tests. "Clinically significant" will be determined by the surgeon at the study site.
15. Subjects who will be unavailable for the duration of the trial, deemed unable to comply with the requirements of the study protocol, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason.
16. Subjects who show a 20% reduction in wound size between screening and baseline.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
S.L.A. Pharma AG
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arda Isik
Role: PRINCIPAL_INVESTIGATOR
Study Principal Investigator
Ozan Kucuk
Role: PRINCIPAL_INVESTIGATOR
Study Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erzincan Binali Yıldırım University General Surgery Clinic
Erzincan, , Turkey (Türkiye)
Site Status
Samsun Training and Research Hospital General Surgery Clinic
Samsun, , Turkey (Türkiye)
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Turkey (Türkiye)
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Akinci OF, Bozer M, Uzunkoy A, Duzgun SA, Coskun A. Incidence and aetiological factors in pilonidal sinus among Turkish soldiers. Eur J Surg. 1999 Apr;165(4):339-42. doi: 10.1080/110241599750006875.
Reference Type
BACKGROUND
Ala S, Saeedi M, Eshghi F, Mirzabeygi P. Topical metronidazole can reduce pain after surgery and pain on defecation in postoperative hemorrhoidectomy. Dis Colon Rectum. 2008 Feb;51(2):235-8. doi: 10.1007/s10350-007-9174-3. Epub 2008 Jan 4.
Reference Type
BACKGROUND
Maeda Y, Ng SC, Durdey P, Burt C, Torkington J, Rao PK, Mayberry J, Moshkovska T, Stone CD, Carapeti E, Vaizey CJ; Topical Metronidazole in Perianal Crohn's Study Group. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease. Br J Surg. 2010 Sep;97(9):1340-7. doi: 10.1002/bjs.7121.
Reference Type
BACKGROUND
Saidy M, Ali A, Adewole A, Ambroze W, Schertzer M, King E, Armstrong D. (2016) Treatment of non-healing pilonidal disease using topical 10% metronidazole: a 10-year review. Annual scientific meeting American Society Colon and Rectal surgeon (ASCRS), April 30-May 4, Los Angeles, USA.
Reference Type
BACKGROUND
Sondenaa K, Andersen E, Nesvik I, Soreide JA. Patient characteristics and symptoms in chronic pilonidal sinus disease. Int J Colorectal Dis. 1995;10(1):39-42. doi: 10.1007/BF00337585.
Reference Type
BACKGROUND
Ypsilantis E, Carapeti E, Chan S. The use of topical 10% metronidazole in the treatment of non-healing pilonidal sinus wounds after surgery. Int J Colorectal Dis. 2016 Mar;31(3):765-7. doi: 10.1007/s00384-015-2269-8. Epub 2015 May 24. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MET-PS-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
NCT06052956
NOT_YET_RECRUITING
PHASE2
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
NCT02447172
COMPLETED
PHASE3
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers
NCT01138436
COMPLETED
PHASE2
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
NCT05608187
TERMINATED
PHASE2
A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
NCT01154374
COMPLETED
PHASE2
Fitostimoline® Hydrogel Versus Saline Gauze Dressing in Diabetic Foot Ulcers
NCT05661474
COMPLETED
PHASE4
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
NCT06674980
RECRUITING
NA
A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds
NCT01081522
COMPLETED
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
NCT02427802
COMPLETED
PHASE3
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
NCT02154087
TERMINATED
PHASE2
Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin
NCT02675335
WITHDRAWN
PHASE3
Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies
NCT05921292
COMPLETED
EARLY_PHASE1
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
NCT00316537
TERMINATED
PHASE1/PHASE2
Wound Powder for Pressure Ulcers at End-of-life
NCT02008487
COMPLETED
NA
Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers
NCT00235196
COMPLETED
PHASE4
Controlling Malodour In Fungating Wounds Using A Cinnamon-Based Dressing: Observational Study
NCT05650762
UNKNOWN
NA
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
NCT01737762
COMPLETED
PHASE3
Zinc Oxide VS MEBO
NCT07193849
RECRUITING
PHASE4
A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers
NCT05739149
RECRUITING
NA
A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers
NCT01143714
COMPLETED
PHASE4
Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers
NCT07161830
RECRUITING
NA
Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
NCT06035536
COMPLETED
NA
Study on the Effectiveness of Hypothermal Sulphurous Water in Wound Hygiene
NCT06725797
ENROLLING_BY_INVITATION
NA
A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix
NCT06444906
NOT_YET_RECRUITING
NA
Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
NCT01359735
COMPLETED
PHASE2